cro.directory
← Compare landing

uBriGene vs VIRSCIO

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryuBriGeneVIRSCIO
SummaryuBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.Virscio is a preclinical CRO offering non-human primate studies, histopathology, and molecular biology services. It supports IND-enabling efficacy, safety, and PK/PD programs in CNS, ophthalmology, and cardiometabolic areas.
Services
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Analytical Method Development & Validation
  • Translational Research
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • Specialized & Large-Animal Models
  • Clinical Imaging Core Lab
  • Regulatory Affairs
  • Translational Research
  • Pathology & Histology Services
Modalities
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
Indications
  • Oncology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Ophthalmology
Phases
  • Discovery
  • Preclinical (General)
  • Preclinical (IND-Enabling)
  • Discovery
  • Preclinical (General)
  • Preclinical (IND-Enabling)
Sourcing models
  • Full-Service Outsourcing (FSO)
Data not yet provided.
Locations
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
  • New Haven, New Haven, CT, United States
  • Headquarters, New Haven, CT, US
Certifications
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
Data not yet provided.

Find similar companies

uBriGene alternatives · VIRSCIO alternatives

Markdown mirror: /compare/ubrigene/virscio.md